Table 2 Patient description Patient no.... | American Society of Hematology

Table 2

Patient description

Patient no.	Disease stage	Response to therapy	Response duration, mo	BCR/ABL positivity, %	BCR/ABL mutations	FTase mutations
1	AP	Partial HR	10	100	E292V	I107V
2	AP	None	0	100	G250E, M351T	Y361L C95R
3	CP	Partial CR	<15	88.33	None	None
4	CP	Partial HR	12	30.24	None	None
5	AP	None	0	NA	None	None
6	CP	None	0	100	None	None
7	CP	None	0	100	G250E	None
8	AP	CHR	2	NA	F359V	None
9	AP	SD	3	9.148	E279L	None
10*	NA	NA	NA	NA	NA	Y361H

Patient no.	Disease stage	Response to therapy	Response duration, mo	BCR/ABL positivity, %	BCR/ABL mutations	FTase mutations
1	AP	Partial HR	10	100	E292V	I107V
2	AP	None	0	100	G250E, M351T	Y361L C95R
3	CP	Partial CR	<15	88.33	None	None
4	CP	Partial HR	12	30.24	None	None
5	AP	None	0	NA	None	None
6	CP	None	0	100	None	None
7	CP	None	0	100	G250E	None
8	AP	CHR	2	NA	F359V	None
9	AP	SD	3	9.148	E279L	None
10*	NA	NA	NA	NA	NA	Y361H

AP indicates accelerated phase; CP, chronic phase; CHR, complete hematologic response; SD, stable disease; and NA, not available.

Patient 10 decided not to enter the study. Only a baseline sample was collected.